NZ604583A - Oral formulations of kinase inhibitors - Google Patents
Oral formulations of kinase inhibitorsInfo
- Publication number
- NZ604583A NZ604583A NZ604583A NZ60458311A NZ604583A NZ 604583 A NZ604583 A NZ 604583A NZ 604583 A NZ604583 A NZ 604583A NZ 60458311 A NZ60458311 A NZ 60458311A NZ 604583 A NZ604583 A NZ 604583A
- Authority
- NZ
- New Zealand
- Prior art keywords
- patients
- formulations
- fak
- peg
- oral formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 abstract 3
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- IFFLKGMDBKQMAH-UHFFFAOYSA-N 2,4-diaminopyridine Chemical class NC1=CC=NC(N)=C1 IFFLKGMDBKQMAH-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35969410P | 2010-06-29 | 2010-06-29 | |
| PCT/US2011/042162 WO2012006081A1 (en) | 2010-06-29 | 2011-06-28 | Oral formulation of kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ604583A true NZ604583A (en) | 2015-04-24 |
Family
ID=45441513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ604583A NZ604583A (en) | 2010-06-29 | 2011-06-28 | Oral formulations of kinase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9375402B2 (OSRAM) |
| EP (1) | EP2588081A4 (OSRAM) |
| JP (1) | JP5936609B2 (OSRAM) |
| CN (1) | CN103313697B (OSRAM) |
| AU (1) | AU2011276552B2 (OSRAM) |
| CA (1) | CA2803004A1 (OSRAM) |
| MX (1) | MX340819B (OSRAM) |
| NZ (1) | NZ604583A (OSRAM) |
| WO (1) | WO2012006081A1 (OSRAM) |
| ZA (1) | ZA201300009B (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012216894B2 (en) | 2011-02-17 | 2016-07-14 | Cancer Therapeutics Crc Pty Limited | Selective FAK inhibitors |
| US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| CN104427976B (zh) | 2012-05-10 | 2018-04-24 | 佩因拉佛姆有限公司 | 疏水的活性成分的储库制剂及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656182A (en) | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
| US20040006005A1 (en) * | 2002-07-02 | 2004-01-08 | Sanjay Bhanot | Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| DE60137069D1 (de) * | 2000-10-11 | 2009-01-29 | Cephalon Inc | Arzneizusammensetzungen enthaltend modafinilverbindungen |
| AR040456A1 (es) | 2002-06-27 | 2005-04-06 | Bristol Myers Squibb Co | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana |
| US20080119515A1 (en) * | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| GT200500310A (es) * | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| JP5247154B2 (ja) | 2005-02-18 | 2013-07-24 | テイボテク・フアーマシユーチカルズ | Ｈｉｖ阻害性２−（４−シアノフェニルアミノ）ピリミジンオキシド誘導体 |
| US20070104780A1 (en) * | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
| EP2012753A2 (en) | 2006-04-28 | 2009-01-14 | Schering Corporation | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| KR20090033904A (ko) | 2006-07-21 | 2009-04-06 | 노파르티스 아게 | 벤즈이미다졸릴 피리딜 에테르의 제제 |
| CA2681015C (en) * | 2007-03-16 | 2016-06-21 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| US20100317663A1 (en) | 2008-02-19 | 2010-12-16 | Jerry Leroy Adams | Anilinopyridines as inhibitors of fak |
| JP5551689B2 (ja) | 2008-06-17 | 2014-07-16 | アストラゼネカ アクチボラグ | ピリジン化合物 |
| WO2011019943A1 (en) | 2009-08-12 | 2011-02-17 | Poniard Pharmaceuticals, Inc. | Method of promoting apoptosis and inhibiting metastasis |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
-
2011
- 2011-06-28 EP EP11804122.7A patent/EP2588081A4/en not_active Withdrawn
- 2011-06-28 AU AU2011276552A patent/AU2011276552B2/en not_active Ceased
- 2011-06-28 NZ NZ604583A patent/NZ604583A/en not_active IP Right Cessation
- 2011-06-28 CN CN201180042122.1A patent/CN103313697B/zh not_active Expired - Fee Related
- 2011-06-28 WO PCT/US2011/042162 patent/WO2012006081A1/en not_active Ceased
- 2011-06-28 CA CA2803004A patent/CA2803004A1/en not_active Abandoned
- 2011-06-28 JP JP2013518572A patent/JP5936609B2/ja not_active Expired - Fee Related
- 2011-06-28 MX MX2012014982A patent/MX340819B/es active IP Right Grant
-
2013
- 2013-01-02 ZA ZA2013/00009A patent/ZA201300009B/en unknown
- 2013-08-14 US US13/967,270 patent/US9375402B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012006081A1 (en) | 2012-01-12 |
| JP2013529686A (ja) | 2013-07-22 |
| JP5936609B2 (ja) | 2016-06-22 |
| CA2803004A1 (en) | 2012-01-12 |
| CN103313697A (zh) | 2013-09-18 |
| US20140206692A1 (en) | 2014-07-24 |
| EP2588081A1 (en) | 2013-05-08 |
| US9375402B2 (en) | 2016-06-28 |
| AU2011276552A1 (en) | 2013-01-10 |
| ZA201300009B (en) | 2013-09-25 |
| CN103313697B (zh) | 2016-06-01 |
| EP2588081A4 (en) | 2014-12-10 |
| MX340819B (es) | 2016-07-26 |
| MX2012014982A (es) | 2013-07-03 |
| AU2011276552B2 (en) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009013804A (es) | Inhibidores novedosos de transcriptasa inversa de vih. | |
| GT201400196A (es) | Compuestos de heterociclilo | |
| EA200900213A1 (ru) | Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич | |
| EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
| GT201300159A (es) | Composiciones y metodos para modular el fxr | |
| PA8803201A1 (es) | Derivados acidos de cicloalquilamino | |
| UA108640C2 (uk) | Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a | |
| WO2012032415A3 (en) | Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin | |
| TNSN08178A1 (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| EP2449114A4 (en) | NEW LIPID FORMULATIONS FOR THE DELIVERY OF THERAPY AGENTS IN SOLID TUMORS | |
| GEP20125459B (en) | Compounds for inhibiting mitotic progression | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| MX2012003469A (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores fosfodiesterasa 10a. | |
| TW200722421A (en) | Azole derivatives as inhibitors of lipases and phospholipases | |
| MX2009010485A (es) | Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas. | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| DOP2012000264A (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| EA201891050A1 (ru) | Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 | |
| WO2014106800A8 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| MX2010005714A (es) | Compuestos de piridina. | |
| AR063027A1 (es) | Derivados de sulfonamida | |
| CY1110213T1 (el) | Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων | |
| MX340819B (es) | Formulacion oral de inhibidores de quinasa. | |
| TW200730513A (en) | Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases | |
| MA31295B1 (fr) | 5-oxo-isoxazoles en tant qu'inhibiteurs de lipases et de phospholipases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: VERASTEM, INC, US Effective date: 20140313 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 JUN 2018 BY COMPUTER PACKAGES INC Effective date: 20150818 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2019 BY COMPUTER PACKAGES INC Effective date: 20180918 |
|
| LAPS | Patent lapsed |